Leaving behind pegylated interferon-based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO

Affiliations

¹ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
² Liver Unit, University Hospitals Birmingham, Birmingham, UK.

Editorial

Jeffrey V Lazarus et al. Liver Int. 2018 Nov.

. 2018 Nov;38(11):1902-1905.

doi: 10.1111/liv.13944.

¹ Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
² Liver Unit, University Hospitals Birmingham, Birmingham, UK.

No abstract available

Comment on

Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong.
Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, Chan JMC, Lai KB, Loo CK, Ng ACY, Lai MS, Chan CW, Lau JYL, Fan TTT, Hui AJ, Lam BCY, Cheung WI, Tsang OTY, Lam K, Lai LSW, Luk WF, Li MKK, Lao WC, Lam JTW, Tsang SWC, Kung KN, Chow WH, Tong RKN, Lui TKL, Shan EHS, Yuen MF, Wong VWS. Hui YT, et al. Liver Int. 2018 Nov;38(11):1911-1919. doi: 10.1111/liv.13926. Epub 2018 Jul 30. Liver Int. 2018. PMID: 29981176